PHAR
Pharming Group NV
NASDAQ: PHAR · HEALTHCARE · BIOTECHNOLOGY
$12.26
+3.29% today
Updated 2026-10-28
Market cap
$681.59M
P/E ratio
74.08
P/S ratio
1.86x
EPS (TTM)
$0.13
Dividend yield
—
52W range
$9 – $21
Volume
0.0M
Pharming Group NV (PHAR) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$12.26
12-Month target
$1.87
2030 Target
—
Intrinsic (DCF)
$11.18
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.2B | $0.2B | $0.2B | $0.3B | $0.4B | $0.4B | $0.5B | $0.5B | $0.6B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 12.13% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 2.54%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.